Sun Pharmaceutical Industries Limited (SUNPHARMA) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally.
Total Assets Chart for Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited (SUNPHARMA) total assets for FY2026 were INR 1087.9B, a 18.1% change from FY2025. Sun Pharmaceutical Industries Limited's total assets grew from INR 15.2B in 2004 to INR 1087.9B in 2026 (7043.1% over 22 years). Total assets compound annual growth rate: 5-year CAGR of 10.0%, 10-year CAGR of 7.2%, 20-year CAGR of 18.0%.
Total Assets (Indian Rupees)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ₹4.59T
- Implied Share Price
- ₹1913.30
- Enterprise Value
- ₹4.27T
- Revenue (TTM)
- ₹599.11B
- EBITDA
- ₹165.83B
- Profit Margin
- 20.19%
- Trailing P/E
- 38.01
- Forward P/E
- 30.58
- Price/Book (MRQ)
- 5.45
- Price/Sales (TTM)
- 7.66
- EV/EBITDA
- 22.01
- EV/Revenue
- 7.16
- Dividend Yield
- 0.00%
- Book Value
- ₹348.31
- Free Cash Flow (FY2026)
- ₹92.42B
- Free Cash Flow Yield
- 2.01%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.